Infliximab may help prevent post-operative Crohn's disease recurrence

February 02, 2009

The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To date, there have been no randomized controlled trials evaluating infliximab for postoperative Crohn's disease prevention.

"Our study provides strong evidence that infliximab is effective at preventing endoscopic, clinical and histological postoperative recurrence of Crohn's disease, and provides a rationale for aggressive postoperative chemoprevention with biologic therapy," said Miguel Regueiro, MD, of the University of Pittsburgh Medical Center. "We are encouraged by our findings, which warrant future study of the duration of post-operative infliximab maintenance and appropriate endoscopic follow up."

Crohn's disease is an inflammation and ulceration process that occurs in the deep layers of the intestinal wall and commonly recurs after intestinal resection. Despite the advent of immunomodulator therapy, approximately 75 percent of Crohn's disease patients require an intestinal resection for complications.

Researchers randomly assigned 24 Crohn's disease patients who had undergone ileocolonic resection to receive intravenous infliximab (5 mg/kg), administered within four weeks of surgery and continued for one year, or placebo. The study's research team elected to use endoscopic recurrence at one year as the primary study endpoint. Secondary endpoints were clinical recurrence and remission and histological recurrence.

At one year, the rate of endoscopic recurrence was significantly lower in the infliximab group (9.1 percent) compared to the placebo group (84.6 percent). There was a non-significant higher proportion of patients in clinical remission in the infliximab group (80 percent) compared to the placebo group (53.8 percent). The histological recurrence rate at one year was significantly lower in the infliximab group (27.3 percent) compared to the placebo group (84.6 percent).

American Gastroenterological Association

---

---

	Infliximab delivers in severe psoriatic arthritis.(Skin Disorders): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on September 15, 2004. The length of the article is 777 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infliximab delivers in severe psoriatic arthritis.(Skin Disorders) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: September 15, 2004 Publisher: International Medical News Group Volume: 34 Issue: 18 Page: 23(1) Distributed by Thomson...
	Infliximab: Pharmacology, Uses and Limitations by Antonio D. Medrano Acevedo (Editor), Montserrat Fajardo Gaitan (Editor) Infliximab is an established therapy for some auto-immune diseases like rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and ulcerative colitis. In this book, the authors present current research in the study of the pharmacology, uses and limitations of infliximab. Topics discussed include the risk of infection in patients treated with infliximab; the efficacy and safety of infliximab during pregnancy and breastfeeding in women with inflammatory bowel disease; and disease activity, treatment response and drug continuation rates among patients with rheumatoid arthritis treated with infliximab.
	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial.(WASHINGTON WHISPERS): An article from: Journal of Drugs in Dermatology by Thomson Gale (Publisher) This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on February 1, 2006. The length of the article is 906 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial.(WASHINGTON WHISPERS) Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: February 1, 2006 Publisher: Thomson Gale Volume: 5 Issue: 2 Page: 197(2) Distributed by Thomson...
	Immunomodulators aid infliximab against Crohn's: agents cut in half the rate of antibody development in patients receiving episodic infliximab ... An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on December 15, 2004. The length of the article is 563 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Immunomodulators aid infliximab against Crohn's: agents cut in half the rate of antibody development in patients receiving episodic infliximab treatment.(Gastroenterology) Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: December 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 24 Page:...
	Infliximab safe in Crohn's with strictures, stenosis.(Digestive Disorders): An article from: Family Practice News by Sharon Worcester (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2005. The length of the article is 622 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infliximab safe in Crohn's with strictures, stenosis.(Digestive Disorders) Author: Sharon Worcester Publication: Family Practice News (Magazine/Journal) Date: January 1, 2005 Publisher: International Medical News Group Volume: 35 Issue: 1 Page: 50(1) Distributed by Thomson...
	Infliximab quells psoriatic arthritis symptoms.(Rx): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on August 15, 2004. The length of the article is 765 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infliximab quells psoriatic arthritis symptoms.(Rx) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: August 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 16 Page: 29(1) Distributed by Thomson...
	No shortage of treatment options for IBD: use azathioprine before infliximab. (Clinical Rounds).(inflammatory bowel disease ): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on June 1, 2003. The length of the article is 1075 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: No shortage of treatment options for IBD: use azathioprine before infliximab. (Clinical Rounds).(inflammatory bowel disease ) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 11 Page: 27(1) Distributed by Thomson...
	Behcet's syndrome may respond to infliximab. (Six Cases).: An article from: Skin & Allergy News by Nancy Walsh (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2003. The length of the article is 5505 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Behcet's syndrome may respond to infliximab. (Six Cases). Author: Nancy Walsh Publication: Skin & Allergy News (Magazine/Journal) Date: July 1, 2003 Publisher: International Medical News Group Volume: 34 Issue: 7 Page: 35(1) Distributed by Thomson...
	Infliximab improved psoriasis by 75% in nearly 90% of patients. (Study of 249 Patients).: An article from: Skin & Allergy News by Betsy Bates (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2003. The length of the article is 657 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Infliximab improved psoriasis by 75% in nearly 90% of patients. (Study of 249 Patients). Author: Betsy Bates Publication: Skin & Allergy News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 34 Issue: 6 Page: 4(1) Distributed by Thomson...
	Remicade[R] (infliximab) studied for treating psoriatic arthritis.(New Products): An article from: Dermatology Nursing by Jannetti Publications, Inc. (Publisher) This digital document is an article from Dermatology Nursing, published by Jannetti Publications, Inc. on August 1, 2003. The length of the article is 3987 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Remicade[R] (infliximab) studied for treating psoriatic arthritis.(New Products) Publication: Dermatology Nursing (Refereed) Date: August 1, 2003 Publisher: Jannetti Publications, Inc. Volume: 15 Issue: 4 Page: 384(1) Distributed by Thomson...